PharmacoEconomics & Outcomes News 784, p26 - 12 Aug 2017 Rotarix reduces resource use and healthcare costs in USA GlaxoSmithKline’s (GSK’s) rotavirus vaccine, Rotarix [RIX 44414; RV1], reduces rotavirus (RV)- and diarrhoea-related resource use and healthcare costs in the US, according to findings of a GSK-funded study published in Vaccine. Data from Truven Commercial Claims and Encounters Databases were used to evaluate the public health impact of Rotarix vaccination in 225 587 commercially- insured children born between 2007 and 2010 and followed until up to five years of age. In total, 34 928 infants received complete vaccination (two doses), 8390 infants received incomplete vaccination (one dose), and 182 269 were unvaccinated. Compared with the unvaccinated cohort, the incidence of first episodes of rotavirus was significantly lower in the cohort who received complete vaccination (incidence rate ratio [IRR] 0.17; 95% CI 0.09, 0.30) or incomplete vaccination (IRR 0.19; 95% CI 0.06, 0.58). Rates of rotavirus-related inpatient, outpatient and emergency room (ER) visits, and diarrhoea-related inpatient and ER visits, were significantly lower in the cohort who received complete vaccination than in the unvaccinated cohort. Rates of rotavirus-related inpatient and ER visits were also significantly lower in the partially vaccinated cohort. The adjusted mean cost for first rotavirus episode was reduced by $11 511 per 1000 patients in the completely vaccinated cohort compared with the unvaccinated cohort, and the adjusted mean cost for first diarrhoea episode was reduced by $46 772 per 1000 patients. "Given the effectiveness of RV1 vaccination and RV vaccination in general, efforts should focus on improving RV vaccination rates which lag behind most pediatric vaccination rates and continue to fall below the Healthy People 2020 target of 80%," commented the authors. * 2012 US dollars Krishnarajah G, et al. Public health impact of Rotarix vaccination among commercially insured children in the United States. Vaccine : Aug 2017. Available from: URL: http://doi.org/10.1016/j.vaccine.2017.06.034 803263873 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784
PharmacoEconomics & Outcomes News – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera